Shifting Sands: How Trump’s Health Policies and emerging Treatments Will Define the Future of Chronic Disease
Table of Contents
As 2025 draws to a close, chronic diseases remain a defining challenge for American public health, increasingly shaped by the policies of the Trump governance and the influence of health Secretary Robert F. Kennedy Jr. While initial efforts to address these enduring ailments yielded some visible changes – from commission reports to altered nutritional assistance programs – deeper systemic issues persist. The administration’s legacy, thus far, is marked by a dramatic overhaul of vaccine policy and a growing skepticism towards established scientific consensus, setting the stage for a pivotal 2026.
The coming year will be critical, with three key areas poised to significantly impact the landscape of chronic disease: the effects of reduced GLP-1 drug prices, the unveiling of potentially radical new dietary guidelines, and the allocation of a record-breaking $50 billion investment in rural health initiatives.
The GLP-1 Revolution: Access, Affordability, and Unforeseen Consequences
the efficacy of blockbuster GLP-1 drugs – Ozempic, Wegovy, and Zepbound – has even swayed a traditionally fiscally conservative president and a health secretary known for his skepticism towards pharmaceutical companies. Lower negotiated prices on these obesity medications, a key initiative of the Trump administration, could represent the most impactful public health achievement of Kennedy’s tenure to date.
Obesity,type 2 diabetes,and related conditions are major contributors to disability and death in the U.S., carrying a tremendous economic burden. Despite their high cost – evidenced by a surge in prescription drug spending in 2025 – GLP-1s have demonstrated significant effectiveness in inducing weight loss and reducing cardiovascular risk. Increased access to these medications is expected to drive down rates of prevalent chronic conditions, with early data suggesting a slight decrease in obesity rates this year potentially linked to their use.
However, the potential extends beyond weight management. Emerging evidence suggests GLP-1s may also be beneficial in treating substance use disorders,offering a potential boon to public health by curbing addiction. Heavy alcohol use, a frequently underestimated driver of chronic conditions like liver disease and certain cancers, could be notably impacted.
Despite the promise, significant questions remain. While initial studies indicate a generally mild side effect profile, long-term safety data is crucial. Rare but serious issues – including pancreatitis, kidney stones, arthritis, suicidal thinking, and eye disease – require further investigation. Concerns also exist regarding potential reductions in lean mass and the risk of sarcopenia. Pharmaceutical companies
The Rural Health Conversion Program: A test of Priorities
The $50 billion Rural health Transformation Program, the largest investment in rural healthcare as the Medicare Modernization Act of 2003. While ostensibly aimed at supporting struggling rural hospitals and clinics facing Medicaid cuts, the program’s true direction will depend on adherence to the MAHA agenda.
Half of the funds will be distributed equally among applying states, with another quarter allocated based on rurality. However, the remaining $12.5 billion will be awarded to states whose proposals align most closely with Kennedy’s vision for rural health. States were encouraged to prioritize “new and emerging technologies” for prevention and chronic disease management, and also “data and technology driven solutions” to improve access to care.
Several states have already submitted proposals outlining their plans. Montana’s proposal focuses on five key solutions: expanded technology use, a stronger workforce, financial solvency, modernized care delivery, and a community-centered approach to prevention. New York prioritizes care coordination, primary care access, behavioral health services, and addressing the incidence of chronic conditions.Indiana, building on its “Make Indiana Healthy Again” program, aims to leverage technology to promote healthy eating in food deserts, potentially integrating nutrition incentives directly onto SNAP benefits cards. Texas’s “Rural Texas Strong” initiative focuses on deploying consumer-facing technology, upgrading equipment, and bolstering the rural healthcare workforce.
These projects represent a diverse range of approaches to address the unique challenges faced by rural communities. The winning states will receive federal funding to implement their plans and, ultimately, demonstrate what works in improving chronic disease outcomes in underserved areas.
The year 2026 promises to be a defining one for chronic disease in America, shaped by the ongoing influence of the Trump administration’s policies and the potential of emerging medical and nutritional interventions.